Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Auricman who wrote (10878)	1/11/1999 2:12:00 PM
From: DR. MEADE	Read Replies (1) \| Respond to of 25711

More APPI news today, and its important ********* Monday January 11, 12:50 pm Eastern Time Company Press Release SOURCE: Advanced Plant Pharmaceuticals, Inc. Advanced Plant Pharmaceuticals, Inc. - APPI - Announces the Launching of their Patent Pending Immune System Supplement 'ACA' in the United States and International Markets NEW YORK, Jan. 11 /PRNewswire/ -- Advanced Plant Pharmaceuticals Inc. (OTC Bulletin Board: APPI - news) announced today that they have officially launched their patent pending product ACA for retail sales in the United States and Internationally. Advanced Plant Pharmaceuticals, Inc. has officially launched the nutritional version of Abavca. ACA the standardized pharmaceutical grade nutritional product is targeted for the CFS (Chronic Fatigue Syndrome) and Immune Supplement market. ACA has been proven to strengthen the immune system as well as fight the spread of HIV virus. This is an orally ingested compound that in Pilot studies, Case studies and in In-vitro studies in the USA and other countries has demonstrated reversal of glandular swelling, restoration of well-being and associated weight gain, improvement in response to skin hypersensitivity tests, increase in the circulating concentration of helper T cells (CD4-positive cells); associated with this is an improvement in the CD4/CD8 ratio, with many patients returning to a normal ratio. This type of response is far different from those experienced by users of any one drug regimen currently on the market. People who have access to the expensive new class of drugs called protease inhibitors have seen similar responses when used in combination with AZT or one of the older products, but they are not effective for all people. The struggle for appropriate medication is all the more difficult because scientists and physicians do not have a clear understanding of which drugs work best together and whether a patient will prove to be resistant to any of the drugs in the combination therapy now in use. Also, approximately 100,000 patients have access to these treatments out of an estimated population of 21.8 million people worldwide who are infected. The CFS and Immune markets are estimated to be in excess of 6 billion dollars annually. The total nutritional supplement market is estimated to be in excess of 23 billion dollars annually in the USA. Prior distribution agreements signed with Klien Associates of Israel and Maxwell Associates of England include the distribution of ACA. Both Companies believe that this product will have immediate market acceptance. APPI will seek distribution partners who are capable of gaining access to the areas of the world with the most patients, India, Southeast Asia and Africa specifically. ACA will be available on the Company web site located at advancedplantpharm.com within the week. On the pharmaceutical side APPI has an approved IND for a Phase I/II clinical trial for the use of Abavca in the treatment of AIDS. This trial is anticipated to begin enrolling patients in the 3rd quarter of 1999, following the completion of further regulatory studies, which will be completed in March. This study should last about 9 months and results should be submitted to the FDA within one year from its commencement. The company expects to announce further agreements in the near future. APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has met FDA nutritional specifications for the marketing of its Lo-Chol in the USA, and has received the first IND from the FDA for a whole plant pharmaceutical which has potential as an immunomodulater in the treatment of patients infected with HIV, the virus that causes AIDS. APPI's Whole Plant Pharmaceutical Grade Process is trade secret and patent pending. Utilization of the APPI process converts a whole plant into the best standardized pharmaceutical grade product. This press release contains forward-looking statements. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. SOURCE: Advanced Plant Pharmaceuticals, Inc. ------------------------------------------------------------------------ More Quotes and News:Advanced Plant Pharmaceuticals Inc (OTC BB:APPI - news)Related News Categories: medical/pharmaceutical ------------------------------------------------------------------------ Help ------------------------------------------------------------------------ Copyright © 1999 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. See our Important Disclaimers and Legal Information